Product Description
Nicotinamide is a water-soluble form of vitamin B3 or niacin. It is made in the body by eating niacin-rich foods such as fish, poultry, nuts, legumes, eggs, and cereal grains. Nicotinamide supplements are used to treat skin conditions and niacin deficiencies (Sourced from: https://www.mskcc.org/cancer-care/integrative-medicine/herbs/nicotinamide)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Serbia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Vitamin D Deficiency | Vitamin D Deficiency | Vitamin D Deficiency
Known Adverse Events: Diplopia | Dizziness | Headache | Erythema | Pruritus | Anaphylaxis | Angioedema | Urticaria | Edema
Company: POLYSAN Scientific & Technological Pharmaceutical Company
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, Norway, Russia, United States
Active Clinical Trial Count: 11
Highest Development Phases
Phase 3: Basal Cell Carcinoma|Cholestasis, Intrahepatic|Kidney Diseases|Kidney Transplant|Melanoma|Renal Transplant|Skin Cancer|Squamous Cell Carcinoma
Phase 2: Acute Kidney Injury|Breast Cancer|Heart Cancer|Heart Failure|Inflammation|Multiple System Atrophy|Parkinsonian Disorders|Post Acute COVID-19 Syndrome|Progressive Supranuclear Palsy|Shy-Drager Syndrome|Supranuclear Palsy, Progressive
Phase 1: Anemia, Sickle Cell|Other
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NADAPT | P2 |
Recruiting |
Parkinsonian Disorders|Multiple System Atrophy|Progressive Supranuclear Palsy|Supranuclear Palsy, Progressive|Shy-Drager Syndrome |
2028-12-01 |
|
| SPRINTR | P3 |
Recruiting |
Melanoma|Squamous Cell Carcinoma|Skin Cancer|Basal Cell Carcinoma |
2027-08-01 |
|
| NARNIA | P2 |
Recruiting |
Heart Failure|Breast Cancer|Heart Cancer |
2025-08-01 |
|
| RXA-II-III-Chol-2022 | P3 |
Recruiting |
Cholestasis, Intrahepatic |
2025-05-01 |
41% |
| RXA-II-III-Chol-2022 | P3 |
Recruiting |
Cholestasis, Intrahepatic |
2025-05-01 |
41% |
| RXA-II-III-Chol-2022 | P3 |
Recruiting |
Cholestasis, Intrahepatic |
2025-05-01 |
41% |
| RXA-II-III-Chol-2022 | P3 |
Recruiting |
Cholestasis, Intrahepatic |
2025-05-01 |
41% |